INO Inovio Pharmaceuticals Inc New

Scientists at Propanc Health Group Corporation Pioneer New Treatment in the Fight against Metastatic Cancer
 

When a patient is first struck down with cancer, the first question asked is whether it has spread to other parts of the body.  Sadly, if confirmed the cancer has spread, or metastasized, it often means a death sentence for the patient. Metastatic cancer remains the single biggest cause of death for sufferers. For scientists around the world, finding a solution is considered the Holy Grail of cancer therapies.
 
Dr Julian Kenyon (PPCH Board Member), Medical Director at the Dove Clinic, UK, has treated cancer sufferers for over twenty years.  During this period, he searched around the world for potential new treatments to address this issue.  In the mid 2000’s, he stumbled upon research using pancreatic proenzymes as an effective way to treat cancer.  Used over the last 100 years, debate on the use of pancreatic enzymes (proenzymes in their active form) has been controversial, never having been established as an approved treatment for cancer by the FDA, despite the National Health Institute sponsoring a clinical trial in the late 90’s.  Not one to shy away from controversy, Dr Kenyon treated a number of late stage cancer patients, hoping to extend patient life, and at least offer comfort.  He was astonished by his observations, with a number of patients significantly exceeding life expectancy. Furthermore, no serious side effects were observed from the treatment. If he could catch patients during the earlier stages of the disease, perhaps he could offer a potential long term treatment solution which could really make a difference.
 
Dr Kenyon decided to undertake the research and development necessary to seek approval for this potential new treatment worldwide.  He enlisted the help of Dr Doug Mitchell (PPCH Lead Investors), former Chancellor of Swinburne University in Melbourne, Australia and an active investor in medical research, and Mr James Nathanielsz (PPCH CEO), a qualified biochemist, and pharmaceutical industry executive, who was undertaking post graduate entrepreneurship studies at the time, at Swinburne University. They formed a company in Melbourne, raising the capital needed to fund the initial stages of their research,
 
After successfully establishing a partnership with Bath University, UK, Propanc scientists made several exciting discoveries.  E-Cadherin is a molecule responsible for cell to cell contact, and critical for maintaining normal cell function within an organ, or tissue.  However, for a cancer cell, loss of E-Cadherin means they can split off and spread to other parts of the body, setting off a deadly chain of events.  These rogue cells, labelled cancer stem cells, often lead to a patient becoming struck down with metastatic cancer.  In effect, pancreatic proenzymes were altering a number of pathways critical for tumors to grow and spread.  It was akin to altering traffic flow, rather than designing a small molecule to stop a single lane of traffic. This presented a potentially exciting new opportunity, as often tumors develop new pathways which render small molecules ineffective.  Consequently, Propanc scientists were able to file patents in regions such as Europe, United States, and Australia/ New Zealand.  So far they have received grant status in several countries and under examination in others.
 
Having established their research and development programs, as well as successfully going public on the Over the Counter Bulletin Board in the United States through a parent entity, Propanc Health Group Corporation, the current Directors at Propanc intend to complete the R&D activities necessary to take their pancreatic proenzyme formulation into human trials.  Their goal is to seek Europen and FDA approval of their treatment for metastatic cancer.  Their vision is to eventually treat early stage patients so they can live with, and even possibly overcome the disease in a similar way that anti-viral treatments revolutionized the AIDS epidemic, by successfully managing viral load in HIV patients.  Perhaps one day,  with Propanc's help metastatic cancer may no longer be considered a death sentence it was once thought to be.  

Similar Companies to Propanc Health Group Corp. ( PPCH ) that are listed on major exchanges include:


Merrimack Pharmaceuticals, Inc. is a promising developmental stage cancer company that is largely overlooked by the retail community. The company's lead clinical candidate is a liposomal encapsulation of Pfizer's colon cancer drug irinotecan, which Merrimack has dubbed "MM-398." In theory, the liposomal encapsulation should increase absorption of irinotecan into the tumor and allow for higher dosings that increase the drug's clinical benefit.


Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the potential development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers.

Inovio Pharmaceuticals Inc. a clinical stage biopharmaceutical company, develops DNA based vaccines
and immune therapies, called synthetic vaccines, in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Inovio’s synthetic vaccines are based on the Company’s SynCon vaccine design. 

 

About regalconsultingllc.com

RegalConsultingLLC.com is a leading independent research, advisory and consulting firm serving Investors, Publicly Traded Companies, Private Companies and The Financial Community.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Regal Consulting, LLC which owns www.RegalConsultingLLC.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Regal Consulting, LLC. which owns www.RegalConsultingLLC.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Regal Consulting, LLC. which owns www.RegalConsultingLLC.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Contact Information:

RegalConsultingLLC.com

702-575-9157

RegalConsutlingLLC@gmail.com